Why Science? | ICH E2E Pharmacovigilance Planning and Safety Specification

The guidance helps sponsors plan pharmacovigilance activities before and around approval, when wider use may expose rare events, longer latency and populations underrepresented in trials. It applies to chemical entities, biotechnology-derived products and vaccines.

The planning discipline in e2e prepares for early postmarketing learning is to connect each uncertainty with a method and decision. The guidance helps sponsors plan pharmacovigilance activities before and around approval, when wider use may expose rare events, longer latency and populations underrepresented in trials. It applies to chemical entities, biotechnology-derived products and vaccines. Keep this boundary visible: The plan complements ongoing clinical safety obligations and regional risk-management requirements.

A strong science note separates observation from interpretation. State the lifecycle stage, planned indications, populations and decisions the plan must support. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

FDA lists E2E as final guidance dated April 2005 under docket FDA-2004-D-0245, issued by CDER and CBER. It can support a stand-alone regional document or relevant sections incorporated into the Common Technical Document.

For the april 2005 fda guidance is final, naming a risk category is the start of inquiry rather than its conclusion. FDA lists E2E as final guidance dated April 2005 under docket FDA-2004-D-0245, issued by CDER and CBER. It can support a stand-alone regional document or relevant sections incorporated into the Common Technical Document. Preserve this guardrail: Current regional formats may organise the same principles differently.

A strong science note separates observation from interpretation. Create a source receipt with title, date, final status, docket, issuing centres and regional implementation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The specification synthesises important nonclinical and clinical safety findings, limitations of the human safety database, populations not studied sufficiently, identified and potential risks, interactions, epidemiology and possible class effects.

A useful plan for the safety specification is a structured summary evolves as the evidence changes. The specification synthesises important nonclinical and clinical safety findings, limitations of the human safety database, populations not studied sufficiently, identified and potential risks, interactions, epidemiology and possible class effects. Remember: A long list is not useful unless it distinguishes evidence strength and importance.

A strong science note separates observation from interpretation. For each item, record evidence, population, consequence, uncertainty and current action. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

An identified risk has adequate evidence of association with the product. Planning considers frequency, seriousness, preventability, reversibility, mechanism, risk factors and how well routine data can monitor it.

The planning discipline in important identified risks have supporting evidence is to connect each uncertainty with a method and decision. An identified risk has adequate evidence of association with the product. Planning considers frequency, seriousness, preventability, reversibility, mechanism, risk factors and how well routine data can monitor it. Keep this boundary visible: “Identified” does not imply that every reported case was caused by the product.

A strong science note separates observation from interpretation. Define the evidence establishing the association and the residual question. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A potential risk has a scientific basis for suspicion but the association is not confirmed. Nonclinical findings, pharmacology, class experience or limited clinical patterns can create such concerns.

For important potential risks remain plausible, naming a risk category is the start of inquiry rather than its conclusion. A potential risk has a scientific basis for suspicion but the association is not confirmed. Nonclinical findings, pharmacology, class experience or limited clinical patterns can create such concerns. Preserve this guardrail: Plausibility should not be presented as established incidence or causality.

A strong science note separates observation from interpretation. State the hypothesis, competing explanations and evidence that would strengthen or weaken it. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Limited study in pregnancy, paediatrics, older adults, organ impairment, diverse ancestries, comorbidity, interactions or long-term use may be important when those exposures are expected. The category focuses attention on decisions that lack adequate evidence.

A useful plan for missing information names consequential gaps evolves as the evidence changes. Limited study in pregnancy, paediatrics, older adults, organ impairment, diverse ancestries, comorbidity, interactions or long-term use may be important when those exposures are expected. The category focuses attention on decisions that lack adequate evidence. Remember: Not every absent subgroup analysis is important missing information.

A strong science note separates observation from interpretation. Link each gap to expected use, plausible consequence and a realistic evidence route. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Incidence, prevalence, mortality, comorbidities, concomitant treatment and natural history help distinguish product-associated patterns from events expected in the treated population. Background rates also inform study feasibility and signal interpretation.

The planning discipline in disease epidemiology provides the background is to connect each uncertainty with a method and decision. Incidence, prevalence, mortality, comorbidities, concomitant treatment and natural history help distinguish product-associated patterns from events expected in the treated population. Background rates also inform study feasibility and signal interpretation. Keep this boundary visible: Population averages may not represent the product’s actual users or the relevant observation window.

A strong science note separates observation from interpretation. Specify population, geography, calendar time, outcome definition and data source for every background rate. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Spontaneous case collection, expedited reporting, periodic reports, literature review, signal detection and follow-up form the routine system. For products without special concerns, well-run routine activities may address the safety specification.

For routine pharmacovigilance is the baseline, naming a risk category is the start of inquiry rather than its conclusion. Spontaneous case collection, expedited reporting, periodic reports, literature review, signal detection and follow-up form the routine system. For products without special concerns, well-run routine activities may address the safety specification. Preserve this guardrail: Routine systems have under-reporting, stimulated reporting and limited denominators.

A strong science note separates observation from interpretation. Map each safety issue to the routine data that can inform it and the blind spots that remain. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Structured questionnaires or focused follow-up can improve information on important events, exposures or special populations. Questions should gather clinically useful detail without overwhelming reporters or delaying essential action.

A useful plan for targeted follow-up can deepen case information evolves as the evidence changes. Structured questionnaires or focused follow-up can improve information on important events, exposures or special populations. Questions should gather clinically useful detail without overwhelming reporters or delaying essential action. Remember: A questionnaire cannot create an unbiased denominator or control group.

A strong science note separates observation from interpretation. Design the shortest form that resolves the safety decision and pilot it with case processors. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A product or disease registry can collect longitudinal exposure and outcomes in pregnancy, rare disease or other priority groups. Disease registries may provide treated and untreated comparisons, while product registries focus on exposed people.

The planning discipline in registries follow defined populations is to connect each uncertainty with a method and decision. A product or disease registry can collect longitudinal exposure and outcomes in pregnancy, rare disease or other priority groups. Disease registries may provide treated and untreated comparisons, while product registries focus on exposed people. Keep this boundary visible: Selection, loss to follow-up and incomplete comparison can limit inference.

A strong science note separates observation from interpretation. Define entry, comparator, outcome ascertainment, follow-up and retention measures before launch. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Cohort, case-control and database studies estimate associations using real-world data. Design should match the question and address confounding, bias, exposure definition, outcome validation and adequate sample size.

For observational studies can test safety hypotheses, naming a risk category is the start of inquiry rather than its conclusion. Cohort, case-control and database studies estimate associations using real-world data. Design should match the question and address confounding, bias, exposure definition, outcome validation and adequate sample size. Preserve this guardrail: A large database does not automatically make a study valid or clinically relevant.

A strong science note separates observation from interpretation. Write a target question before selecting the data source and analysis. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Additional trials or extensions can provide controlled exposure, laboratory monitoring or data in particular populations. They may be appropriate when the question cannot be resolved through passive surveillance or observational data alone.

A useful plan for clinical studies may answer focused uncertainties evolves as the evidence changes. Additional trials or extensions can provide controlled exposure, laboratory monitoring or data in particular populations. They may be appropriate when the question cannot be resolved through passive surveillance or observational data alone. Remember: Trials can still be too small or selective for rare or long-latency outcomes.

A strong science note separates observation from interpretation. Match design, endpoint, duration and population to the unresolved safety question. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Signal detection, incidence estimation, causal evaluation and risk-factor identification require different data. E2E encourages choosing activities because they address a specified concern rather than because a method is fashionable or readily available.

The planning discipline in method choice depends on the safety question is to connect each uncertainty with a method and decision. Signal detection, incidence estimation, causal evaluation and risk-factor identification require different data. E2E encourages choosing activities because they address a specified concern rather than because a method is fashionable or readily available. Keep this boundary visible: One activity rarely answers every dimension of a complex risk.

A strong science note separates observation from interpretation. Create a question-method-decision matrix and expose gaps between them. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A useful plan states data availability, eligible population, expected events, operational responsibilities, timelines and analysis. Unfeasible commitments delay learning and may create false assurance.

For feasibility belongs in the plan, naming a risk category is the start of inquiry rather than its conclusion. A useful plan states data availability, eligible population, expected events, operational responsibilities, timelines and analysis. Unfeasible commitments delay learning and may create false assurance. Preserve this guardrail: Feasibility should not be used to avoid an important safety question without proposing an alternative.

A strong science note separates observation from interpretation. Estimate recruitment, events, follow-up and data latency before committing milestones. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Protocol dates, study starts, interim analyses, reporting points and decision gates allow regulators and teams to see whether the plan is progressing. Milestones can be revised when assumptions change, with reasons documented.

A useful plan for milestones make learning accountable evolves as the evidence changes. Protocol dates, study starts, interim analyses, reporting points and decision gates allow regulators and teams to see whether the plan is progressing. Milestones can be revised when assumptions change, with reasons documented. Remember: A completed activity is not necessarily a resolved safety issue.

A strong science note separates observation from interpretation. Define both delivery milestones and evidence-based stopping or escalation criteria. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

New cases, studies, literature or class information can create, refine or refute a concern. The safety specification and pharmacovigilance plan should evolve as evidence changes, with urgent issues acted on outside routine cycles.

The planning discipline in signals should update the specification and plan is to connect each uncertainty with a method and decision. New cases, studies, literature or class information can create, refine or refute a concern. The safety specification and pharmacovigilance plan should evolve as evidence changes, with urgent issues acted on outside routine cycles. Keep this boundary visible: An annual update cadence must not delay action on an immediate threat.

A strong science note separates observation from interpretation. Set triggers for escalation, protocol change, communication and new investigation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The receipt records product and population, identified and potential risks, missing information, epidemiology, routine activities, targeted methods, feasibility, milestones, signal criteria, outputs, decisions and revision history. It makes the plan testable.

For a complete e2e receipt joins question to action, naming a risk category is the start of inquiry rather than its conclusion. The receipt records product and population, identified and potential risks, missing information, epidemiology, routine activities, targeted methods, feasibility, milestones, signal criteria, outputs, decisions and revision history. It makes the plan testable. Preserve this guardrail: A detailed plan has value only when data are reviewed and decisions follow.

A strong science note separates observation from interpretation. Give the receipt to an independent safety scientist and ask which important uncertainty lacks a credible path. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter